GLA developed by Immune Design demonstrated ability to increase vaccine immunogenicity in humans in several clinical and preclinical studies.
Immune Design president and chief executive officer Carlos Paya said, "Partnering with SCYNEXIS, with its efficient and cost-effective chemistry synthesis process, moves us closer to delivering important vaccine products to those in need."
Scynexis will act as cGMP production partner for manufacturing the clinical stage synthetic TLR4 agonist.
Scynexis president and chief executive officer Yves Ribeill said, "At SCYNEXIS, we always welcome the opportunity to join forces and solve the challenges of complex chemistry projects while creating innovative solutions with our partners."